In vitro and in vivo immunogenicity assessment of protein aggregate characteristics-Reference-Cited by-同舟云学术

In vitro and in vivo immunogenicity assessment of protein aggregate characteristics

Published:2023-01 Issue: Volume:631 Page:122490
ISSN:0378-5173
Container-title:International Journal of Pharmaceutics
language:en
Short-container-title:International Journal of Pharmaceutics

Author:

Thorlaksen Camilla,Schultz Heidi S.,Gammelgaard Simon K.,Jiskoot Wim,Hatzakis Nikos S.,Nielsen Flemming S.,Solberg Helene,Foderà Vito,Bartholdy Christina,Groenning Minna

Funder

Novo Nordisk

Novo Nordisk Fonden

Villum Fonden

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference58 articles.

1. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics;Ahmadi;Pharm. Res.,2015

2. Characterization and quantitation of aggregates and particles in interferon-beta products: potential links between product quality attributes and immunogenicity;Barnard;J. Pharm. Sci.,2013

3. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective;Bee;J. Pharm. Sci.,2012

4. Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines;Benne;J. Control. Release,2016

5. Extensive chemical modifications in the primary protein structure of igg1 subvisible particles are necessary for breaking immune tolerance;Boll;Mol. Pharm.,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Directional freezing and thawing of biologics in drug substance bottles;European Journal of Pharmaceutics and Biopharmaceutics;2024-10

2. Evaluating Clinical Safety and Analytical Impact of Subvisible Silicone Oil Particles in Biopharmaceutical Products;Journal of Pharmaceutical Sciences;2024-05

3. A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic;Pharmaceutical Research;2024-03-22

4. Streamlining biosimilar development based on 20 years’ experience;Expert Opinion on Biological Therapy;2024-02-22

5. Assessment of subvisible particles in biopharmaceuticals with image feature extraction and machine learning;Chemometrics and Intelligent Laboratory Systems;2024-02